Cuba’s Abdala and Soberana 02 Vaccines Near the Finish Line
The Abdala vaccine showed 92.28% efficacy with three doses during the third phase of clinical trials and the Soberana 02 vaccine showed 62% efficacy with just two of its three doses.
Peoples Dispatch
"In name of Cuba, congratulations," said Miguel Díaz-Canel to the researchers of CIGB that worked to create Abdala, the anti-COVID-19 vaccine. Photo: Granma
Cuban state-owned pharmaceutical company BioCubaFarma, on June 21, reported that the country’s locally developed anti-COVID-19 vaccine candidate, Abdala of the Center for Genetic Engineering and Biotechnology (CIGB), showed 92.28% efficacy with three doses during the third phase of clinical trials. The significant news came two days after the news that another vaccine candidate, Soberana 02 of the Finlay ...










